MTS invests in Ovagen Fertility

Los Angeles-based Ovagen Fertility, a network of assistive reproductive technology labs, has secured an undisclosed investment from MTS Health Investors. No financial terms were disclosed. In addition to the funding, Dr. Kaylen Silverberg and Dr. George Hill have been added to Ovagen’s board of directors.

PRESS RELEASE

NEW YORK, June 23, 2015 — MTS Health Investors, LLC (“MTS”), the New-York based healthcare private equity firm, announced today that funds managed by MTS have completed an equity investment in Ovagen Fertility (“Ovagen” or “the company”). Ovagen is a platform of industry-leading assistive reproductive technology (“ART”) laboratories in four states performing all aspects of treatment and testing for infertility patients, including laboratory and genetic services as part of the in-vitro fertilization (“IVF”) process. Ovagen laboratories affiliate with leading physician fertility clinics across the US to provide the highest quality of patient care in reproductive medicine. MTS partnered with the physician owners and an experienced healthcare management team to provide capital to support future growth and advances in technology. Terms of the transaction were not disclosed.

Two of the founding physician partners, Dr. Kaylen Silverberg and Dr. George Hill, will serve as members of Ovagen’s Board of Directors. “Our partnership with Ovagen and MTS creates a premier platform to provide our patients with the highest levels of quality, innovation and patient care as we address the most challenging infertility treatments,” said Dr. Silverberg.

MTS Managing Director Alex Buzik said, “We are thrilled to be partnering with such a well-respected group of physicians through Ovagen. Their collective clinical achievements and state-of-the-art laboratory services offer the best results for patients. We look forward to providing additional financial resources and continuing to invest in the Ovagen network.”

Ovagen’s senior management team will be led by co-founder Nate Snyder, who will serve as Chief Executive Officer. Mr. Snyder will be supported by an advisory committee of physicians and lab directors who will have extensive involvement in the oversight of all clinical processes.

“Ovagen Fertility represents a fresh perspective on IVF lab management. The company’s unique structure encourages a collaborative approach across established market leaders, effectively cultivating innovation and optimizing patient outcomes,” commented Mr. Snyder.

About Ovagen Fertility
Ovagen Fertility, headquartered in Los Angeles, California, is a premier network of assistive reproductive technology (“ART”) laboratories performing all aspects of treatment and testing for infertility patients, including embryology, andrology and genetics services as part of the in-vitro fertilization process. The company partners with prominent physician clinics that are committed to advancing the industry standard in IVF services. For further information, please visit www.ovagenfertility.com.

About MTS
MTS Health Investors, LLC, located in New York, is a healthcare private equity firm that makes investments in operating companies within the healthcare industry. MTS focuses on companies that deliver greater value for every dollar spent in healthcare. Industry sectors in which MTS invests include: providers of outsourced solutions to the healthcare industry; providers of direct medical services to patients in an institutional, ambulatory, or home setting; providers of managed care and other healthcare insurance services; distributors of medical products; and manufacturers of low-technology medical devices and supplies. For further information, please visit www.mtshealthinvestors.com.